Pharmacoeconomic evaluation of Simulect prophylaxis in renal transplant recipients

Transplant Proc. 2001 Nov-Dec;33(7-8):3187-91. doi: 10.1016/s0041-1345(01)02356-9.
No abstract available

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Antibodies, Monoclonal / economics
  • Antibodies, Monoclonal / pharmacokinetics
  • Antibodies, Monoclonal / therapeutic use*
  • Basiliximab
  • Biopsy
  • Costs and Cost Analysis
  • Double-Blind Method
  • England
  • Humans
  • Kidney Transplantation / economics
  • Kidney Transplantation / immunology*
  • Kidney Transplantation / mortality
  • Length of Stay
  • Placebos
  • Postoperative Complications / classification
  • Postoperative Complications / epidemiology
  • Recombinant Fusion Proteins / economics
  • Recombinant Fusion Proteins / pharmacokinetics
  • Recombinant Fusion Proteins / therapeutic use
  • Survival Rate
  • Treatment Failure
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Placebos
  • Recombinant Fusion Proteins
  • Basiliximab